LAUSR

REFERENCES 1. Di Nisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. New Engl J Med. 2005;353:1028-1040. 2. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838-1843. 3. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ, American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141: 7S-47S. https://doi.org/10.1378/chest.1412S3. 4. Shaikh S, Van Cott EM. The effect of argatroban on activated protein C resistance. Am J Clin Pathol. 2009;131:828-833. https://doi.org/10. 1309/AJCPVMUS77ZMBEHJ. 5. Kim YA, Gosselin R, Van Cott EM. The effects of dabigatran on lupus anticoagulant, diluted plasma thrombin time, and other specialized coagulation assays. Int J Lab Hematol. 2015;37:e81-e84. https://doi. org/10.1111/ijlh.12319. 6. Genzen JR, Miller JL. Presence of direct thrombin inhibitors can affect the results and interpretation of lupus anticoagulant testing. Am J Clin Pathol. 2005;124:586-593. 7. Seheult JN, Meyer MP, Bontempo FA, Chibisov I. The effects of indirectand direct-acting anticoagulants on lupus anticoagulant assays: a large, retrospective study at a coagulation reference laboratory. Am J Clin Pathol. 2017;147:632-640. https://doi.org/10.1093/ajcp/aqx035. 8. Gosselin RC, King JH, Janatpur KA, Dager WH, Larkin EC, Owings JT. Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing. Arch Pathol Lab Med. 2004;128:1142-1145. 9. US Food and Drug Administration. NDA 20-883/S-014. Argatroban Injection. Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_ docs/label/2008/020883s014lbl.pdf. Accessed January 5, 2018.